Danish diabetes powerhouse Novo Nordisk A/S delivered record Japan sales of 89 billion yen in 2015, up 6% over the previous year, buoyed by its long-acting insulin analog Tresiba (insulin degludec) and Victoza (liraglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist,…
To read the full story
Related Article
- Novo Japan Chalks Up Record Sales in 2016 on Tresiba, Victoza
April 13, 2017
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
BUSINESS
- Santen Snags China Rights to 5 Glaucoma Drugs from AbbVie
April 20, 2026
- AbbVie Launches Aquipta Migraine Drug in Japan
April 20, 2026
- Fronteo, Astellas Partner on AI-Driven Drug Target Discovery
April 20, 2026
- Towa to Outsource 1.5 Billion Tablets to Adragos by 2033
April 20, 2026
- Lilly’s Omvoh 200 mg SC Wins Japan Nod for UC Maintenance Use
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





